Nausea/Vomiting and Altered Mental Status in a Patient with Metastatic NSCLC

Share this content:
  • Advanced Stage NSCLC
  • Fluorodeoxyglucose FDG-PET Scan
  • Bronchopulmonary SCLC
  • PET/CT Fusion Imaging
  • 3D CT Scan Model
  • MRI Scan Showing SCLC
  • Lung Tumor Invading an Alveolus
  • Masses in Both Lungs
  • Small Cell Lung Cancer

Lung Cancer


A 65-year-old female with metastatic non-small cell lung cancer (NSCLC) of squamous cell histology presents with nausea/vomiting and changes in mental status. She is due for day 8 gemcitabine.

History Seven days ago, the patient received cycle 2 of cisplatin and gemcitabine for her NSCLC. The patient's husband states that his wife took antiemetics as directed, but noticed she had become disoriented and confused over the last 2 days. She is still taking her antiemetic prochlorperazine every 4 hours with minimal relief.

Her medical history includes hypertension and Stage IV NSCLC with bone metastasis. She was taking the following medications: hydrochlorothiazide 25mg daily, prochlorperazine 10mg every 4 hours as needed for nausea/vomiting, dexamethasone 8mg daily for 3 days postchemotherapy, and aprepitant 80mg daily for 2 days postchemotherapy.

Her laboratory test results were as follows:

Na 140mEq/L            WBC 4.5

K    3.4mEq/L            Hgb 12g/dL

CL  110mEq/L            Plts 140

CO2 24                       Albumin 2.4g/dL

BUN 48mg/dL           

Scr 1.6mg/dL

Ca 14mg/dL

Click NEXT to view the patient's diagnosis and an explanation.

Page 1 of 3

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs